Alpha 2.0
Login Register
» Authors » Naomi Serling-Boyd

Naomi Serling-Boyd

Explore the profile of Naomi Serling-Boyd including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 312
Followers 0
Related Specialties
Rheumatology
Oncology
Top 10 Co-Authors
Kristin M DSilva
Jeffrey A Sparks
Zachary S Wallace
Rachel Wallwork
Tiffany Y-T Hsu
Tiffany Hsu
Zachary Scott Wallace
Xiaoqing Fu
Ellen M Gravallese
Hyon Choi
Published In
Ann Rheum Dis
Curr Opin Rheumatol
Semin Arthritis Rheum
Mol Clin Oncol
Arthritis Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C
DSilva K, Serling-Boyd N, Hsu T, Sparks J, Wallace Z
Ann Rheum Dis . 2021 Mar; 82(6):e131. PMID: 33692020
No abstract available.
2.
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
DSilva K, Serling-Boyd N, Hsu T, Sparks J, Wallace Z
Ann Rheum Dis . 2021 Jan; 80(6):817-819. PMID: 33436385
No abstract available.
3.
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic
Serling-Boyd N, DSilva K, Hsu T, Wallwork R, Fu X, Gravallese E, et al.
Ann Rheum Dis . 2020 Dec; 80(5):660-666. PMID: 33257496
Objective: In earlier studies, patients with rheumatic and musculoskeletal disease (RMD) who got infected with COVID-19 had a higher risk of mechanical ventilation than comparators. We sought to determine COVID-19...
4.
A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura
Goreshnik A, Serling-Boyd N, Theodore M, Champion S, Stemmer-Rachamimov A, Sykes D
Rheumatology (Oxford) . 2020 Nov; 60(4):e143-e145. PMID: 33221867
No abstract available.
5.
Management of primary vasculitides with biologic and novel small molecule medications
Serling-Boyd N, Wallace Z
Curr Opin Rheumatol . 2020 Nov; 33(1):8-14. PMID: 33164993
Purpose Of Review: Vasculitides can affect small, medium and/or large vessels, leading to end-organ damage, decreased quality of life and death. Glucocorticoids remain the backbone of treatment for systemic vasculitis...
6.
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry
Gianfrancesco M, Leykina L, Izadi Z, Taylor T, Sparks J, Harrison C, et al.
Arthritis Rheumatol . 2020 Nov; 73(3):374-380. PMID: 33146001
Objective: Racial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID-19) in the general US population. This study was undertaken to examine the association between race/ethnicity and COVID-19 hospitalization,...
7.
Gastric antral vascular ectasia in systemic sclerosis: Association with anti-RNA polymerase III and negative anti-nuclear antibodies
Serling-Boyd N, Chung M, Li S, Becker L, Fernandez-Becker N, Clarke J, et al.
Semin Arthritis Rheum . 2020 Sep; 50(5):938-942. PMID: 32906028
Objective: Gastric antral vascular ectasia (GAVE) is a vascular manifestation of systemic sclerosis (SSc) that can lead to iron deficiency anemia or acute gastrointestinal (GI) bleeding. We aimed to identify...
8.
The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
Serling-Boyd N, Mohareb A, Kim A, Hyle E, Wallace Z
Ann Rheum Dis . 2020 Aug; 80(2):274-276. PMID: 32732241
No abstract available.
9.
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques
DSilva K, Serling-Boyd N, Wallwork R, Hsu T, Sparks J, Wallace Z
Ann Rheum Dis . 2020 Jul; 81(8):e135. PMID: 32660976
No abstract available.
10.
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani
DSilva K, Serling-Boyd N, Wallwork R, Hsu T, Sparks J, Wallace Z
Ann Rheum Dis . 2020 Jun; 81(7):e132. PMID: 32586919
No abstract available.